Indeed, we have recently reported that the combined targeting of BCL-xL and MCL-1 with a platelet-sparing BCL-xL proteolysis targeting chimera (PROTAC) degrader (DT2216) and an mTOR inhibitor (AZD8055) is effective in inhibiting tumor growth in SCLC preclinical models without causing the on-target toxicities associated with BCL-xL and MCL-1 inhibitors [26]. The gene discussed is BCL2L1; the disease is neoplasm.